Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Infliximab
Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease
